In peculiar, a longitudinal study of two CLL patients who achieved clinical remission after treatment with FCR or BR confirmed the results obtained in the small cohort of patients in remission: serum NGAL levels were much lower after treatment than at the full-blown disease stage, and returned to control values. Here, LCN2 is linked to B-cell chronic lymphocytic leukemia.